Albert Bourla, Pfizer’s chairman and chief executive, said in a statement that “ultimately, we believe that three doses of the vaccine will be needed for children 6 months through 4 years of age to achieve high levels of protection against current and potential future variants.” But he said that if two doses are authorized in…
